Interferons
| Zeile 5: | Zeile 5: | ||
{{tp|p=32333818|t=2020. COVID-19: lambda interferon against viral load and hyperinflammation |pdf=|usr=}} | {{tp|p=32333818|t=2020. COVID-19: lambda interferon against viral load and hyperinflammation |pdf=|usr=}} | ||
{{tp|p=21093489|t=2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model |pdf=|usr=}} | {{tp|p=21093489|t=2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model |pdf=|usr=}} | ||
| + | {{tp|p=32483527|t=2020. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a.|pdf=|usr=008}} | ||
Version vom 27. Juni 2020, 20:40 Uhr
32301957 ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19
32275914 2020. Type 1 interferons as a potential treatment against COVID-19
32360182 2020. Antiviral activities of type I interferons to SARS-CoV-2 infection
32289152 2020. COVID-19 and emerging viral infections: The case for interferon lambda
32333818 2020. COVID-19: lambda interferon against viral load and hyperinflammation
21093489 2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model
32483527 2020. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a.
